Viewing Study NCT05116969


Ignite Creation Date: 2025-12-24 @ 10:58 PM
Ignite Modification Date: 2026-01-02 @ 5:16 AM
Study NCT ID: NCT05116969
Status: WITHDRAWN
Last Update Posted: 2022-02-17
First Post: 2021-10-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 1 Study of PTX-35 in Healthy Volunteers
Sponsor: Heat Biologics
Organization:

Study Overview

Official Title: A Phase 1, Single Dose-Escalation and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous PTX-35 Adminsitration in Healthy Volunteers
Status: WITHDRAWN
Status Verified Date: 2022-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Sponsor withdrew submission to Human Research Ethics Committee as it evaluates the need for healthy volunteer data for development plan.
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: A Phase 1, Single Dose-Escalation and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous PTX-35 Adminsitration in Healthy Volunteers
Detailed Description: This is a double blind, placebo controlled, Phase 1 study of PTX-35 administered via IV infusion to healthy male and female participants. This study will be conducted in 2 stages:

* Stage 1 is a single ascending dose (SAD) escalation period in which 5 dose levels of PTX-35 will be evaluated.
* Stage 2 is a multiple dose period in which the highest tolerated dose determined from Stage 1 will be tested in 2 different treatment regimens in 2 cohorts (i.e., 7- and 14- days dosing regimen).

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: